PD184352 (CI-1040)

Catalog No.S1020

PD184352 (CI-1040) is an ATP non-competitive MEK1/2 inhibitor with IC50 of 17 nM in cell-based assays, 100-fold more selective for MEK1/2 than MEK5. Phase 2.

Price Stock Quantity  
USD 140 In stock
USD 70 In stock
USD 120 In stock
USD 270 In stock
USD 670 In stock
USD 770 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

PD184352 (CI-1040) Chemical Structure

PD184352 (CI-1040) Chemical Structure
Molecular Weight: 478.67

Validation & Quality Control

Cited by 43 publications:

12 customer reviews :

Quality Control & MSDS

Related Compound Libraries

PD184352 (CI-1040) is available in the following compound libraries:

MEK Inhibitors with Unique Features

Product Information

  • Compare MEK Inhibitors
    Compare MEK Products
  • Research Area
  • Combination Therapy
    Combination Therapy

Product Description

Biological Activity

Description PD184352 (CI-1040) is an ATP non-competitive MEK1/2 inhibitor with IC50 of 17 nM in cell-based assays, 100-fold more selective for MEK1/2 than MEK5. Phase 2.
Targets MEK1 [1]
(Cell-free assay)
MEK2 [1]
(Cell-free assay)
IC50 17 nM 17 nM
In vitro CI-1040 treatment produces a reduction of pMAPK levels in multiple tumor cells including Colon 26, BX-PC3 pancreatic, A431 cervical, HT-29 colon, ZR-25-1 breast and SKOV-3 ovarian carcinomas. CI-1040 treatment doesn't inhibit the phosphorylation of Jun kinase, p38 kinase or Akt, indicating CI-1040 specifically targets MEK. Inhibition of MAPK activation by CI-1040 prevents cell cycle progression and induces a G1 block. [1] The IC50 for inhibition of MEK1 by CI-1040 is 0.3 μM, 15-fold higher than the concentration required to inhibit the EGF-induced activation of ERK2 in Swiss 3T3 cells. These results indicate CI-1040 exerts its effects on cells by suppressing the activation of MKK1, and not by blocking its activity. 2 nM PD184352 inhibits the activation of MKK1 in Swiss 3T3 cells by 50%, while over 100-fold concentration of CI-1040 inhibits MEK1 in vitro. PD184352 also inhibits the Raf-catalysed phosphorylation of MEK1 without any effect on the Raf-catalysed phosphorylation of myelin basic protein. [2] CI-1040 inhibits 86% of papillary thyroid carcinoma (PTC) cell growth with the RET/PTC1 rearrangement at 10μM compared with cells treated with DMSO only. CI-1040 shows potent inhibition to PTC cells (BRAF mutation) with GI50 of 52 nM, but low activity to RET/PTC1 rearrangement type with GI50 of 1.1 μM. [3] A recent research indicates CI-1040 increases the apoptotic effect of BMS-214662 in a CML blast crisis cell line, K562, and in primary chronic phase CD34+ CML cells. [4]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
H9NX3oc3k{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NH\XUHFKSzVyPUCuNFIzPzZizszNNHPX[2xUSU6JRWK=
CHP-212NF3P[ZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFzYO4JKSzVyPUCuNFI5QDVizszNM13TUnNCVkeHUh?=
EoL-1-cellM4fOe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlXLTWM2OD1yLkC0NVUzKM7:TR?=M3vMb3NCVkeHUh?=
DU-4475MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MojpTWM2OD1yLkC3OVk6KM7:TR?=NIW1dIxUSU6JRWK=
MMAC-SFMVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXHJR|UxRTBwMUC5O|Qh|ryPMo\mV2FPT0WU
AGSMWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4TxSGlEPTB;MD6xNVcyOyEQvF2=MnvIV2FPT0WU
M14MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mm\BTWM2OD1yLkG1OFY5KM7:TR?=MV7TRW5ITVJ?
CP50-MEL-BMoDRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIDvSpZKSzVyPUCuNVczPTRizszNNHz6TVVUSU6JRWK=
C32NXKwWpU2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF20fYpKSzVyPUCuNVkxPzJizszNM3;NUXNCVkeHUh?=
KMOE-2MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVzJR|UxRTBwMUm3PVUh|ryPMV3TRW5ITVJ?
A101DNX\FVHJvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn35TWM2OD1yLkKxOEDPxE1?M{iwfHNCVkeHUh?=
KM12Mm\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVnPUGg1UUN3ME2wMlI1ODV5IN88US=>NXvPeJNGW0GQR1XS
HSC-4MoLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXTJR|UxRTBwMkSzPVUh|ryPNGHrbIRUSU6JRWK=
NOMO-1NEH5c5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NF;wNHJKSzVyPUCuNlU4PDJizszNM17UbXNCVkeHUh?=
MZ7-melMortS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYjJR|UxRTBwMk[zOEDPxE1?MoPyV2FPT0WU
ACNNH3ve2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1XLUGlEPTB;MD6yOlc{PyEQvF2=NI\xdZJUSU6JRWK=
MEL-HONHv6fHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH\XfVRKSzVyPUCuNlc3PTJizszNM{T6[HNCVkeHUh?=
BHT-101NHvIdHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFLuSnJKSzVyPUCuNlg3ODZizszNMYfTRW5ITVJ?
SK-MEL-28MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEDadYtKSzVyPUCuN|A1ODlizszNNWLsZm5vW0GQR1XS
KG-1Mo[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX3zVFk1UUN3ME2wMlMxPjZ6IN88US=>NE[3W2pUSU6JRWK=
COLO-679MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGXTXIVKSzVyPUCuN|I4OiEQvF2=NH7RdGxUSU6JRWK=
SK-MEL-24MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NX;SPYR4UUN3ME2wMlMzQDF|IN88US=>NHzNSJFUSU6JRWK=
G-361MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1XYTGlEPTB;MD6zOlc6PSEQvF2=NWHRUmxvW0GQR1XS
KY821M3e0O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV\JR|UxRTBwM{e5NUDPxE1?M{n5eXNCVkeHUh?=
KASUMI-1M4mwVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEHZWoNKSzVyPUCuN|k6KM7:TR?=M1L1UnNCVkeHUh?=
HL-60NFXHb4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2\0TGlEPTB;MD60NVExPyEQvF2=M{nkbXNCVkeHUh?=
K5MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWHWWGs{UUN3ME2wMlQ{OTF5IN88US=>MlrpV2FPT0WU
KU812M3[2[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2D1V2lEPTB;MD60OVI6QSEQvF2=M1y3XXNCVkeHUh?=
SH-4MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXXmVJc1UUN3ME2wMlQ3OjV4IN88US=>NWTWfYY2W0GQR1XS
HTC-C3NXLidXBwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUnJR|UxRTBwNE[1N|Eh|ryPM4TibnNCVkeHUh?=
CP66-MELMlfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlvnTWM2OD1yLkS4PFA6KM7:TR?=MnH6V2FPT0WU
WM-115MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUHnXW4zUUN3ME2wMlQ6OjV5IN88US=>M3\XZXNCVkeHUh?=
A2780Mn\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHLaS5hKSzVyPUCuOFk5OjNizszNNGjqUpFUSU6JRWK=
P12-ICHIKAWAMoPkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVHJR|UxRTBwNkGyNlEh|ryPMlP2V2FPT0WU
HMV-IINFT1UFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV\UUopJUUN3ME2wMlY1PDZ3IN88US=>NHLJZXBUSU6JRWK=
HT-144MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVPJR|UxRTBwNkS2OVch|ryPNVLQeJlrW0GQR1XS
LB2518-MELMXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYDp[mJxUUN3ME2wMlcyPjN{IN88US=>NGDjUFlUSU6JRWK=
NCI-SNU-1MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVvJR|UxRTBwN{W0N|Mh|ryPMlSwV2FPT0WU
C2BBe1NGnTNZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{HFZ2lEPTB;MD64NVAzOyEQvF2=MVvTRW5ITVJ?
PSN1MlPPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3ntOGlEPTB;MD65OlE6PiEQvF2=NGH6blJUSU6JRWK=
UACC-257M3fTe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYPGRnVRUUN3ME2wMlk3PDd|IN88US=>MkHhV2FPT0WU
RVH-421NHnVR5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUfJR|UxRTBwOUexPEDPxE1?M2OwXXNCVkeHUh?=
GP5dMWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mn3yTWM2OD1yLkm4N|A5KM7:TR?=Ml3MV2FPT0WU
TYK-nuNIXrZphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoGzTWM2OD1zLkCzNVczKM7:TR?=NYfoXZFPW0GQR1XS
SK-N-ASMkHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2\yNWlEPTB;MT6wO|k1PyEQvF2=MX\TRW5ITVJ?
SW620Mkj6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX3JR|UxRTFwMUO1N|Qh|ryPMYrTRW5ITVJ?
HuP-T4M13XNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NU\vOmRHUUN3ME2xMlE5OzV7IN88US=>MlvmV2FPT0WU
A549MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXjJR|UxRTFwMUm1O|Yh|ryPNWHTflc1W0GQR1XS
MewoNETveFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWnJR|UxRTFwMkCyO|Yh|ryPMoPuV2FPT0WU
ONS-76M3XtU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2ezcWlEPTB;MT6yNlA1QSEQvF2=NFHEU4dUSU6JRWK=
SK-MEL-1MmLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{HMbmlEPTB;MT6yN|QyQSEQvF2=M1O4T3NCVkeHUh?=
RCM-1MoHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGi5VWhKSzVyPUGuNlQxPDdizszNMV7TRW5ITVJ?
H-EMC-SSMV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M122dmlEPTB;MT6yPVYxQCEQvF2=NIjF[4tUSU6JRWK=
NCI-H2291M2SyR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M17yeWlEPTB;MT6zNlU{PiEQvF2=MVrTRW5ITVJ?
SW1463M2LLVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV\JR|UxRTFwM{O3NlEh|ryPNHjEZo1USU6JRWK=
LS-411NM2\GfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4WxW2lEPTB;MT60NFUyPyEQvF2=M4jubnNCVkeHUh?=
BV-173NHH0PJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3;VcGlEPTB;MT60OFAyPSEQvF2=MX3TRW5ITVJ?
LS-513MmfHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHHpeohKSzVyPUGuOFUyQTJizszNM1jMUXNCVkeHUh?=
LoVoM1X3Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkjZTWM2OD1zLkS2N|k6KM7:TR?=NUXEO2YxW0GQR1XS
HO-1-N-1NXLXPYdbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWj0[pNSUUN3ME2xMlUyPjN2IN88US=>Ml3LV2FPT0WU
ML-2NH\JPXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4m5[2lEPTB;MT61Nlg3QCEQvF2=NWXreYdVW0GQR1XS
NCI-H1437M3\rT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVTYR2s{UUN3ME2xMlU2Ojd3IN88US=>NF[4c29USU6JRWK=
SW1116MmP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGC4VmxKSzVyPUGuOVY{QThizszNM{fw[3NCVkeHUh?=
A4-FukNVPoPFY3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUjJR|UxRTFwNUewOFUh|ryPMYXTRW5ITVJ?
HD-MY-ZMnrqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXvxVmp1UUN3ME2xMlU4Ozd4IN88US=>M1jTb3NCVkeHUh?=
SK-MEL-2NEDOVJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mni5TWM2OD1zLkW3OFU6KM7:TR?=M{LWTnNCVkeHUh?=
RT-112M4D4TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGXrRm9KSzVyPUGuOVg6PTJizszNM{PiPHNCVkeHUh?=
COLO-829M4fvVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWXwendxUUN3ME2xMlYzOjN{IN88US=>NF3Td|NUSU6JRWK=
OVCAR-5NHuwbFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mnn0TWM2OD1zLke3Olg4KM7:TR?=NH3MRWhUSU6JRWK=
NB69M1HKVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUDSVIhpUUN3ME2xMlc5PDZ7IN88US=>MWLTRW5ITVJ?
NCI-H292MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFjIeWVKSzVyPUGuPFY3QTlizszNM2PwWXNCVkeHUh?=
LOXIMVIMkLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHf2OpRKSzVyPUGuPFk1OjdizszNNGrXcplUSU6JRWK=
BPH-1MkDpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGjoUItKSzVyPUGuPFk2QTFizszNMkfUV2FPT0WU
A375NHPDepZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVXxWnFsUUN3ME2xMlg6PzF2IN88US=>MXnTRW5ITVJ?
LCLC-97TM1NGXlXVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3vzdmlEPTB;MT65NlI2PiEQvF2=NIm1S29USU6JRWK=
RXF393MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVnJR|UxRTFwOUe4PFch|ryPMmW5V2FPT0WU
HCC70MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NX\4PYRnUUN3ME2yMlAzPDJ4IN88US=>NIPTVYlUSU6JRWK=
EM-2MmLZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEDvOIdKSzVyPUKuNFcyQThizszNMYLTRW5ITVJ?
MZ2-MELNH3sWFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV;JR|UxRTJwMUGxNlch|ryPNFPTTJJUSU6JRWK=
HNNHvTc4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MX\JR|UxRTJwMU[yO|gh|ryPNUTLRnJuW0GQR1XS
A2058MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NILqNYRKSzVyPUKuNVkzPzlizszNM3L4bnNCVkeHUh?=
NB7MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVzJR|UxRTJwM{SwPFYh|ryPNX;hZpRwW0GQR1XS
DOKMWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4L2SGlEPTB;Mj6zOVc4OyEQvF2=MXvTRW5ITVJ?
CAL-27MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWLJR|UxRTJwM{myN|Yh|ryPNIjGc4FUSU6JRWK=
BB65-RCCNEf3[IJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUfTOI9vUUN3ME2yMlQxPjd2IN88US=>M2jI[HNCVkeHUh?=
RDNGTmeGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUPnPYJmUUN3ME2yMlQ1PzJ|IN88US=>MmX3V2FPT0WU
KNS-62M1vJUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFTRZlFKSzVyPUKuOVEyPjRizszNMV7TRW5ITVJ?
EW-13NV;QcYlvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHG0W5RKSzVyPUKuOVY{OzlizszNNV76eHRjW0GQR1XS
DBM{DzO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX\FXpJNUUN3ME2yMlU5Pzh6IN88US=>NVHBWYpOW0GQR1XS
HCC2218MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVTxeGFLUUN3ME2yMlY1Pzd6IN88US=>NUTRdZZWW0GQR1XS
L-363MkfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF[3eIJKSzVyPUKuO|Q{PyEQvF2=MoS0V2FPT0WU
CHL-1M2juemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYfJR|UxRTJwOEC3PFUh|ryPMl\4V2FPT0WU
BFTC-905M{jPcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFP6UFJKSzVyPUKuPFI2OyEQvF2=Mn\uV2FPT0WU
HCE-TMorsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHLTXW5KSzVyPUKuPFMzPjRizszNNVG5[pN4W0GQR1XS
COLO-792MlHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWrJR|UxRTJwOESwNlch|ryPMkLlV2FPT0WU
LB2241-RCCNWrsPIhPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF\wOYFKSzVyPUKuPFU5QTNizszNNF36SHpUSU6JRWK=
CAL-39NI\TbmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWHsV3pkUUN3ME2yMlg6QTl7IN88US=>NVfYdpA4W0GQR1XS
T-24NVHzcGE1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnvXTWM2OD1{LkmxNVEzKM7:TR?=NGLZU|ZUSU6JRWK=
NCI-H727MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnnmTWM2OD1{LkmxO|k3KM7:TR?=NVrYNlNvW0GQR1XS
Ca9-22MoC2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4LhS2lEPTB;Mj65O|I2PSEQvF2=MUXTRW5ITVJ?
MIA-PaCa-2NVnYUnBqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mkf3TWM2OD1|LkCwO|gyKM7:TR?=MWnTRW5ITVJ?
HT-1080NWnRTYxsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX7JR|UxRTNwMEG5PVch|ryPMYrTRW5ITVJ?
D-423MGMkLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NI\kR29KSzVyPUOuNFc4PTNizszNMl3uV2FPT0WU
LAMA-84NVPU[HBkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkWwTWM2OD1|LkGzOVgh|ryPMXzTRW5ITVJ?
SW780NW[2eHZWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NE\NPGxKSzVyPUOuNVQzOjlizszNMmfvV2FPT0WU
KU-19-19M2XlSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkXjTWM2OD1|LkG3NFM1KM7:TR?=NXyyflVXW0GQR1XS
COLO-741NWfIOW1HT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MV3JR|UxRTNwMUi2O|Mh|ryPMVjTRW5ITVJ?
HSC-3MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYXJR|UxRTNwMkOxOVEh|ryPNFGxfXFUSU6JRWK=
SN12CMoCxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWPYZW5nUUN3ME2zMlI1PzBzIN88US=>NFjIVpFUSU6JRWK=
786-0NWKy[o1[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVXJR|UxRTNwMkeyOFMh|ryPMVrTRW5ITVJ?
GAKMYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1rDS2lEPTB;Mz6zNlU3OSEQvF2=NVnUUWNyW0GQR1XS
PANC-03-27MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2m2RWlEPTB;Mz6zOVA1PSEQvF2=NVfGdnBMW0GQR1XS
CTB-1MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYXJR|UxRTNwNEewOFch|ryPM3KyNHNCVkeHUh?=
A427NGHUXmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVjseIh4UUN3ME2zMlU6PTV4IN88US=>MoDpV2FPT0WU
EGI-1NV3BUFJNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnTsTWM2OD1|Lk[wOVg{KM7:TR?=M1TUcXNCVkeHUh?=
U-2-OSNG\YOGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWPJR|UxRTNwNkeyOVYh|ryPM1HGSHNCVkeHUh?=
NCI-SNU-5M2XoTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVfsfpNSUUN3ME2zMlY4PzNizszNMlTrV2FPT0WU
SK-LU-1NHGzWGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4LnOmlEPTB;Mz62PFc6QCEQvF2=MYrTRW5ITVJ?
697Mke1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGG2TZpKSzVyPUOuOlk3ODNizszNNWjKVWdoW0GQR1XS
HPAF-IINEjPXY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkDPTWM2OD1|Lke1OFkh|ryPMoPEV2FPT0WU
NCI-H2087NUP6NVh2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn7OTWM2OD1|Lki0OlczKM7:TR?=M2DiXXNCVkeHUh?=
SK-MEL-3NFfsfVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml3QTWM2OD1|Lki1NVU1KM7:TR?=NHzKTJRUSU6JRWK=
CGTH-W-1MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVzJR|UxRTNwOEW3NlUh|ryPNIOyeGNUSU6JRWK=
8505CNFK5OIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUPiUmIyUUN3ME2zMlkxODd6IN88US=>M4HoOXNCVkeHUh?=
GAMGNFOxb5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFz6U3RKSzVyPUSuNFI{PzdizszNNUXnVm5KW0GQR1XS
SW626MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MonjTWM2OD12LkC0OFgh|ryPMUXTRW5ITVJ?
CAL-62MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV7JR|UxRTRwMEe0N{DPxE1?MkfXV2FPT0WU
MHH-PREB-1MnzPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NELIR4lKSzVyPUSuNVIyOTFizszNNHmyWotUSU6JRWK=
RPMI-7951MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYTyb4p2UUN3ME20MlI2PTh7IN88US=>M3XnVnNCVkeHUh?=
HOP-92MnL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NU\DWphoUUN3ME20MlI2PjdizszNNH:2RYtUSU6JRWK=
MDA-MB-231MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWLZVHROUUN3ME20MlI6OjJ|IN88US=>NVS1[JVoW0GQR1XS
LAN-6NIH6ZnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXvy[2J4UUN3ME20MlMyPjN5IN88US=>MlniV2FPT0WU
ALL-PONXrKcWd7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXHJR|UxRTRwM{[xOVYh|ryPMlHZV2FPT0WU
HHNES4[pNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mme5TWM2OD12LkSxOVk4KM7:TR?=MXLTRW5ITVJ?
IGROV-1NGjPUpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYLBZnJNUUN3ME20MlQ2OTdzIN88US=>MWLTRW5ITVJ?
NCI-H358NEHLSIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHnhcG5KSzVyPUSuOFU{QDVizszNNEi4VHpUSU6JRWK=
NB5NWTMPWdZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUDJR|UxRTRwNkCzOlkh|ryPMUnTRW5ITVJ?
NCI-H747NH7mN|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV\OR5lZUUN3ME20MlY5QDB5IN88US=>MlzEV2FPT0WU
NH-12M2HHVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWTJR|UxRTRwN{G2NlUh|ryPMYfTRW5ITVJ?
LB1047-RCCNV;ETGJTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUPsZ4FTUUN3ME20Mlc{QDF3IN88US=>MV;TRW5ITVJ?
EFO-27MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4frPWlEPTB;ND63PFY3PyEQvF2=NFy4VphUSU6JRWK=
EPLC-272HM4HMXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnvLTWM2OD12Lkm5OlY6KM7:TR?=Mn;hV2FPT0WU
CAL-54M2TSdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV;2cppKUUN3ME21MlAzPjl3IN88US=>MkjCV2FPT0WU
H4NXHIRoZ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUnoVVlsUUN3ME21MlA1OjV3IN88US=>MmfKV2FPT0WU
MOLT-13NH6yXlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX7Vfnc4UUN3ME21MlA3Pzd4IN88US=>MoDXV2FPT0WU
CAL-33NH[0Z4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M37XemlEPTB;NT6xNlMyPyEQvF2=NGW0WJJUSU6JRWK=
23132-87NG\QTXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1PxUGlEPTB;NT6xOlg4OiEQvF2=NWjQepVbW0GQR1XS
UM-UC-3NHTBNG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEnLOnVKSzVyPUWuNVgxPDdizszNMXHTRW5ITVJ?
HuH-7NX6yOHR1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{\BSmlEPTB;NT6yO|E1PyEQvF2=M{DzOnNCVkeHUh?=
BCPAPNUfqdGlyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHfHeGFKSzVyPUWuN|I6PjlizszNNXjU[HByW0GQR1XS
AsPC-1M33scmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUPReWhnUUN3ME21MlM3PzZ|IN88US=>NVXCeGJ5W0GQR1XS
NCI-H1155MlX0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmP0TWM2OD13LkSwNFUyKM7:TR?=NEToZ29USU6JRWK=
GT3TKBNWrSUZBzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUXSUm5JUUN3ME21MlQ3PTl6IN88US=>NWOzPHBHW0GQR1XS
HCC2998M2q4[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3LpNmlEPTB;NT60PVExQSEQvF2=NV\wVm5vW0GQR1XS
NUGC-3MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXjJR|UxRTVwNEmzNFIh|ryPM3jEVXNCVkeHUh?=
Hs-578-TMoTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHe4cWtKSzVyPUWuOVM4QTRizszNNXfyc4piW0GQR1XS
FADUMlHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGGwO|hKSzVyPUWuOVU4OjZizszNNEThUmpUSU6JRWK=
NBsusSRNXLM[Jo2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlvXTWM2OD13LkW3NVU2KM7:TR?=NH;jOIZUSU6JRWK=
ME-180M33Lcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkLQTWM2OD13LkW4NFkzKM7:TR?=MoC2V2FPT0WU
SW1710M2XGVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVfJR|UxRTVwNkG2OVQh|ryPMnviV2FPT0WU
HuP-T3NYHwdmVzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkfyTWM2OD13Lk[yNFI6KM7:TR?=NUf6O2lQW0GQR1XS
HOSM4fUN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVPJR|UxRTVwNkK5NlMh|ryPNVvGV5FWW0GQR1XS
PA-1M3TDcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFq0ZZpKSzVyPUWuOlQzPjVizszNMYjTRW5ITVJ?
LU-99AM3HwRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWPNTYV[UUN3ME21MlY3PDVzIN88US=>NYj6OpRsW0GQR1XS
RS4-11M2\QZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M17QVGlEPTB;NT62Olc4PSEQvF2=M2HTV3NCVkeHUh?=
TE-8NGXuPW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXjJR|UxRTVwNki1N|ch|ryPNXnUcYhrW0GQR1XS
RERF-LC-MSMUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWTDS3dVUUN3ME21MlY5QDB|IN88US=>MVXTRW5ITVJ?
MEL-JUSOM3v4bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX:5bIFyUUN3ME21Mlc{PzhizszNMnG3V2FPT0WU
SK-MES-1NFn5dopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml7pTWM2OD13LkizOVI5KM7:TR?=M1;lOXNCVkeHUh?=
D-263MGNHnRbZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVjLNot1UUN3ME21Mlg5OzVzIN88US=>MWDTRW5ITVJ?
NB10M1r1TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGDiSodKSzVyPUWuPFk1PiEQvF2=M4LFPXNCVkeHUh?=
SK-HEP-1M4XBO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnrFTWM2OD13LkmzOFcyKM7:TR?=M4H2XHNCVkeHUh?=
HT-29NEjIclJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M33YZmlEPTB;NT65PFEyQCEQvF2=Mm[wV2FPT0WU
KYSE-140MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{H2dGlEPTB;Nj6wNlE5OiEQvF2=M1WxcHNCVkeHUh?=
NCI-H1666MoCyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2nW[mlEPTB;Nj6wPFQ3OSEQvF2=NX;lOlRKW0GQR1XS
NCI-H1304MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkfTTWM2OD14LkG5PVQh|ryPNGjzXHJUSU6JRWK=
RPMI-8866MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVzmNmplUUN3ME22MlIyOzF|IN88US=>MlfOV2FPT0WU
MV-4-11M2TyTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2LvW2lEPTB;Nj6yN|E6QSEQvF2=NF;oVWpUSU6JRWK=
A431NUixbZpKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2TJ[GlEPTB;Nj6yOFI6PiEQvF2=MU\TRW5ITVJ?
PANC-10-05NGXTVpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnnsTWM2OD14LkK4N|Y{KM7:TR?=MnnmV2FPT0WU
TK10MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXziUWI4UUN3ME22MlMzPjB2IN88US=>NWHsbFVRW0GQR1XS
NCI-H1975NXnibIV6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnvMTWM2OD14LkS3NlE2KM7:TR?=M1HzO3NCVkeHUh?=
A172MorNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXXJR|UxRTZwNEmxO|Yh|ryPMkm3V2FPT0WU
D-566MGMWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4LwUWlEPTB;Nj61OFMxOyEQvF2=NIXvb5JUSU6JRWK=
NCI-H2122MmfWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGfoc45KSzVyPU[uOlE2OjhizszNMXzTRW5ITVJ?
COR-L105Mn[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXvJR|UxRTZwNkWyO|Uh|ryPNUe2Z2Z3W0GQR1XS
AN3-CAMlL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYrscot{UUN3ME22MlY5PjRzIN88US=>MVrTRW5ITVJ?
Calu-6MlrDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVXJR|UxRTZwN{m2PVgh|ryPM37QVnNCVkeHUh?=
HCT-116NUi0W5g{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF;kSotKSzVyPU[uPFEzPjRizszNNUm4NlhoW0GQR1XS
MHH-NB-11NFvwe2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYPQWWRTUUN3ME22Mlg2ODB{IN88US=>NUDlcYdkW0GQR1XS
MFE-280MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYTJR|UxRTZwOEW5PFMh|ryPNX;UXIVTW0GQR1XS
SW1088NXfqRYVoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NULCO4xzUUN3ME22MlkyQTF|IN88US=>MWLTRW5ITVJ?
SW48MoLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2XaeWlEPTB;Nj65OFUyKM7:TR?=M3jm[HNCVkeHUh?=
HuCCT1NFXHcWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1nhd2lEPTB;Nz6wNVA{PyEQvF2=M4e3OHNCVkeHUh?=
ACHNMoPjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGfWZoFKSzVyPUeuNFI6PDNizszNMnHhV2FPT0WU
8305CM1vCbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF;uXXpKSzVyPUeuNFk6QTVizszNM32wb3NCVkeHUh?=
DoTc2-4510MoDJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3vEbWlEPTB;Nz6xNlE2KM7:TR?=NIftUXJUSU6JRWK=
COR-L23NXXve21tT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlfBTWM2OD15LkK0OFIh|ryPNGOzUFdUSU6JRWK=
SK-MEL-30NWLCU21VT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NELrdZpKSzVyPUeuNlUxQDNizszNMn\sV2FPT0WU
BE-13MmPHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX;JR|UxRTdwM{O4N|Qh|ryPM{G3eXNCVkeHUh?=
GR-STMk\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGK0NWtKSzVyPUeuOFAyPzRizszNMkG3V2FPT0WU
LU-135M{\RRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml;2TWM2OD15LkW1PVM6KM7:TR?=NUPzTYFrW0GQR1XS
U-266NELDV3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml2xTWM2OD15LkW2Nlg3KM7:TR?=MXzTRW5ITVJ?
NCI-H1355Mn\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIDCU3ZKSzVyPUeuOVg3OzVizszNMUTTRW5ITVJ?
NB14MoLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVfJR|UxRTdwNk[2OFIh|ryPMV;TRW5ITVJ?
SCC-25M1rJZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFWyXFlKSzVyPUeuO|A6KM7:TR?=NF7BUoFUSU6JRWK=
COLO-678NEK0codIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlzFTWM2OD15LkexNFc3KM7:TR?=NI\Sb|ZUSU6JRWK=
TGBC1TKBMUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1;VUGlEPTB;Nz64PVM6QCEQvF2=NEHuS2tUSU6JRWK=
IST-MEL1MnP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEC5emJKSzVyPUiuNFA1ODZizszNM1:3R3NCVkeHUh?=
ECC10M2KzO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MY\JR|UxRThwMEOzPVUh|ryPNYLmU4dNW0GQR1XS
EW-16M4\mUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NILleFdKSzVyPUiuNFg1PDVizszNMom4V2FPT0WU
DOHH-2MoDuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MljCTWM2OD16LkKwNFk2KM7:TR?=MleyV2FPT0WU
NCI-H1581M3\nXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2XXbmlEPTB;OD6yOlMzOyEQvF2=NGrwcZJUSU6JRWK=
TE-5M3\vUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2[4W2lEPTB;OD60NlQzQSEQvF2=MWPTRW5ITVJ?
CAKI-1NWTlfGNqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX;6UmVQUUN3ME24MlU4OjJ{IN88US=>NWXHeoxzW0GQR1XS
A673M1XXbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoK2TWM2OD16Lk[zNlAzKM7:TR?=M2nhT3NCVkeHUh?=
CAL-12TMn\xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVHJR|UxRThwNkW3OVMh|ryPNXOybnZkW0GQR1XS
DBTRG-05MGM{DIS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mo\pTWM2OD16Lke0PFU6KM7:TR?=NFvxV2NUSU6JRWK=
SK-N-FINGnmNWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUfJR|UxRThwOEGzO|kh|ryPMU\TRW5ITVJ?
K-562MkDnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXPhWId3UUN3ME24Mlg{QTV5IN88US=>NWG0Unh{W0GQR1XS
SBC-1NFjuTJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4WwZ2lEPTB;OD64OlY1PSEQvF2=MYrTRW5ITVJ?
ES4MmfxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MorwTWM2OD16Lki2PFg1KM7:TR?=NEPzPGJUSU6JRWK=
MS-1M3PpWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M37rfGlEPTB;OD64O|UyPyEQvF2=MVHTRW5ITVJ?
RKOMnzIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXfmeI1PUUN3ME24Mlg6ODV5IN88US=>MWXTRW5ITVJ?
NCI-H1693M4PIbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M371eWlEPTB;OD65NlE4KM7:TR?=MXPTRW5ITVJ?
SW954M4rGUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVW3V4xWUUN3ME24Mlk3QTd6IN88US=>MnPhV2FPT0WU
SK-UT-1Mn\TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mlv3TWM2OD16Lkm3Olg{KM7:TR?=NXn6TmhpW0GQR1XS
T98GMkjoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWT2VItZUUN3ME24Mlk6QDR4IN88US=>MknKV2FPT0WU
NCI-H2126NFPXV5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NU\BWlhqUUN3ME25MlAxQDJ4IN88US=>MYPTRW5ITVJ?
TE-12NXvTU4dRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2rH[mlEPTB;OT6wN|M3PyEQvF2=NH\YTmNUSU6JRWK=
DK-MGNFLDc4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmjBTWM2OD17LkKxNVkyKM7:TR?=NGn2RZJUSU6JRWK=
MEG-01MoLrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXLJR|UxRTlwMkS5N|Eh|ryPNYHCWG1bW0GQR1XS
HCC1937M{HEemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1[5RWlEPTB;OT6yPVA6OSEQvF2=NGjXOIRUSU6JRWK=
MKN45M4DuTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnnmTWM2OD17LkS1NFY2KM7:TR?=MXjTRW5ITVJ?
NCI-H1792NF3VW|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXHJR|UxRTlwNEWyNVkh|ryPMmjPV2FPT0WU
SW1417MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWHJR|UxRTlwNU[4N|ch|ryPNVTEeWZ2W0GQR1XS
639-VNF;rb5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVfqRVhPUUN3ME25MlY1Ozh6IN88US=>NWqz[2FqW0GQR1XS
P30-OHKNGnRNmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVXadlNLUUN3ME25MlY2OzF4IN88US=>MnKyV2FPT0WU
YKG-1NVrEXnZET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVjxU3JUUUN3ME25Mlc2ODN|IN88US=>MXnTRW5ITVJ?
KGNMXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NV;vW3JCUUN3ME25Mlg{Pzl3IN88US=>M4q4NXNCVkeHUh?=
MSTO-211HMk\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFrmZo1KSzVyPUmuPVU2OjlizszNMW\TRW5ITVJ?
NCI-H1573M4PHWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NU\qWYpsUUN3ME2xNE4yPTd2IN88US=>MnKyV2FPT0WU
NCI-H720MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2TnUmlEPTB;MUCuNVk5QSEQvF2=NXvlfFI{W0GQR1XS
KARPAS-45NYrDTWpVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVvHTIZZUUN3ME2xNE4zPzl3IN88US=>M4\q[3NCVkeHUh?=
MDA-MB-175-VIIMX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3W4XWlEPTB;MUCuOFgh|ryPM4TMN3NCVkeHUh?=
SK-NEP-1MnjFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVHJR|UxRTFyLkS5PFEh|ryPNI[1UlVUSU6JRWK=
MKN28MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoXLTWM2OD1zMD61NVgh|ryPMo\2V2FPT0WU
KYSE-520MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVfJR|UxRTFyLkWyJO69VQ>?MmTNV2FPT0WU
KE-37NETIOlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVrJR|UxRTFyLkWyO|Ih|ryPNYn4bZV7W0GQR1XS
VA-ES-BJNFLYXZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVKwc2M6UUN3ME2xNE42PjdizszNMV7TRW5ITVJ?
CCRF-CEMM2TYeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{i4S2lEPTB;MUCuOVY5PCEQvF2=M3\tWnNCVkeHUh?=
GMS-10MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXTJR|UxRTFyLk[wPVQh|ryPMVvTRW5ITVJ?
NCI-H1623M37xZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUfJR|UxRTFyLk[zO|kh|ryPNGDZSYFUSU6JRWK=
NEC8NIHvXIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVHuWZFqUUN3ME2xNE44Pzd|IN88US=>MVnTRW5ITVJ?
MOLT-16NVmyVlZbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{ezUGlEPTB;MUCuPFEyOyEQvF2=MlTNV2FPT0WU
DJM-1NFuySY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NF7zUI1KSzVyPUGxMlA{PzlizszNNHHvSY5USU6JRWK=
U251NFO5e3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MW\JR|UxRTFzLkC0NkDPxE1?MlnsV2FPT0WU
SBC-5MnPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYTJR|UxRTFzLkG0Olch|ryPNWTod5MyW0GQR1XS
SW756MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUX1d2RGUUN3ME2xNU4zOTV2IN88US=>MVHTRW5ITVJ?
KS-1MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGLa[4NKSzVyPUGxMlI3OTlizszNM4G0[HNCVkeHUh?=
SF295MoSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2L4RWlEPTB;MUGuN|ExPCEQvF2=NYT1coc5W0GQR1XS
YH-13MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVXUd5RyUUN3ME2xNU4{OjZ5IN88US=>NEP3W4lUSU6JRWK=
SW837NXPLdmU5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXHJR|UxRTFzLkO1NFYh|ryPMoTsV2FPT0WU
KYSE-450NVP4NI4yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVvFS4ZGUUN3ME2xNU41ODV5IN88US=>MX3TRW5ITVJ?
KYSE-180M33kd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4XEZ2lEPTB;MUGuOFgzKM7:TR?=MlKyV2FPT0WU
S-117MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHTyW2hKSzVyPUGxMlQ5QTZizszNM1fEZnNCVkeHUh?=
KOSC-2NXGz[HRFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1\YXGlEPTB;MUGuOlIzOiEQvF2=MYnTRW5ITVJ?
KYSE-270MlHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1vEcWlEPTB;MUGuPFc1PSEQvF2=M3:wVHNCVkeHUh?=
D-336MGNYGzXpRNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXq2dmdSUUN3ME2xNU46ODd3IN88US=>MoHDV2FPT0WU
KALS-1MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUPoeYR[UUN3ME2xNk4xODF4IN88US=>MnvpV2FPT0WU
LB373-MEL-DM4Xwemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWjJR|UxRTF{LkC1N|Mh|ryPNYDse5RiW0GQR1XS
HLENEDMZY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUnJR|UxRTF{LkC1PFUh|ryPMn3KV2FPT0WU
SJSA-1NYjabFg{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWTIVWFkUUN3ME2xNk4xPzN3IN88US=>NVHVc2hIW0GQR1XS
SW1990NF3Cb2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFu4VXBKSzVyPUGyMlA6OTFizszNMYjTRW5ITVJ?
NOS-1MnXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NH\pfJdKSzVyPUGyMlE{PTJizszNNVXIXndLW0GQR1XS
GI-ME-NMVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUfxcJRTUUN3ME2xNk4zOTZ|IN88US=>Mn\XV2FPT0WU
NCI-H1703MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYC2em9KUUN3ME2xNk4zPjF4IN88US=>Mo\rV2FPT0WU
ES7MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHq0dVFKSzVyPUGyMlI4OjRizszNMkPrV2FPT0WU
KYSE-510M4Hy[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlrJTWM2OD1zMj61NFc6KM7:TR?=NIH5PFJUSU6JRWK=
BHYM4DLZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkTFTWM2OD1zMj61N|A4KM7:TR?=M3uxXXNCVkeHUh?=
TCCSUPMo\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXnyemcyUUN3ME2xNk42PzV5IN88US=>M1PyPXNCVkeHUh?=
HSC-2MoXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MU\JR|UxRTF{LkW5PVYh|ryPNUPDbFM2W0GQR1XS
BENMnPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnrTTWM2OD1zMj62NVQ{KM7:TR?=NXPab3FKW0GQR1XS
769-PNH3UPVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVrJR|UxRTF{Lke5NlQh|ryPMnvwV2FPT0WU
HTM4HHNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1niUmlEPTB;MUKuPFM1PiEQvF2=M33qXXNCVkeHUh?=
LXF-289M{PL[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkDtTWM2OD1zMj65OVMyKM7:TR?=NGfXT3FUSU6JRWK=
OVCAR-3Mn\xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn\rTWM2OD1zMj65OVY4KM7:TR?=M1W2NXNCVkeHUh?=
ATN-1NYrQ[mFoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnjFTWM2OD1zMz6wNVg1KM7:TR?=MXLTRW5ITVJ?
8-MG-BAMX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEXGcW5KSzVyPUGzMlA1PTVizszNNE\YR5lUSU6JRWK=
SW13MnnmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFTZ[HVKSzVyPUGzMlEyPjVizszNMlTqV2FPT0WU
NCI-H1092MoT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NU\vbHB6UUN3ME2xN{4yPjJizszNM2K4SnNCVkeHUh?=
OAW-42MmHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWG0[m11UUN3ME2xN{4yQTN5IN88US=>NXS1UWd{W0GQR1XS
NCI-H2452MlPHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXzQVY5KUUN3ME2xN{4zOTd3IN88US=>NYDl[WtNW0GQR1XS
CAPAN-1NXnPfoNET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2\ucmlEPTB;MUOuOVUyPCEQvF2=NHf0VndUSU6JRWK=
NCI-H2009NHnCfZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYn6SFlZUUN3ME2xN{42QTF7IN88US=>NXfhTHltW0GQR1XS
SF268M1i5bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVHJR|UxRTF|Lk[zNlYh|ryPMYTTRW5ITVJ?
GCIYNEjoZVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEfB[YpKSzVyPUGzMlY6OjdizszNMofTV2FPT0WU
OS-RC-2MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXrJR|UxRTF|Lkm1NFEh|ryPNV\M[HlNW0GQR1XS
GCTNXTwbnR2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoXMTWM2OD1zMz65Olk4KM7:TR?=MUnTRW5ITVJ?
NB17NWnJXWdFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{n3OWlEPTB;MUSuNFg2KM7:TR?=NITmZWRUSU6JRWK=
NCI-H2030NUPYOmtDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV7ONVBuUUN3ME2xOE4yPDZ3IN88US=>NUK2OXEzW0GQR1XS
HC-1Mm\qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mlj2TWM2OD1zND6yNFg4KM7:TR?=Mn\FV2FPT0WU
QIMR-WILNVLF[IlJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXzJR|UxRTF2LkO0NVIh|ryPM1riRXNCVkeHUh?=
Capan-2NID6Tm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVnJR|UxRTF2LkO3NVQh|ryPMYjTRW5ITVJ?
BALL-1NGDCR|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3fxfWlEPTB;MUSuOFY3PSEQvF2=NU\GeIVtW0GQR1XS
LS-1034MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVT6fFI2UUN3ME2xOE43OTV{IN88US=>NGPuW5lUSU6JRWK=
U-118-MGNVf4Z3VYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFfCfYVKSzVyPUG0MlY{OSEQvF2=NH7XdXhUSU6JRWK=
NCI-H630NV76[WFJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3jCNGlEPTB;MUSuOlU3QCEQvF2=Mm\jV2FPT0WU
OVCAR-8MlLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4fPbmlEPTB;MUSuO|IxOSEQvF2=NV33UmdsW0GQR1XS
NCI-H2347NGP0cWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1vteWlEPTB;MUSuPFI{KM7:TR?=NX\DUFlSW0GQR1XS
BT-549M4f4Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3HUO2lEPTB;MUSuPFI5PCEQvF2=MnHrV2FPT0WU
LB831-BLCMVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUjJR|UxRTF2Lki5N|Qh|ryPNWC4T4NFW0GQR1XS
NCI-H661MnjVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX;JR|UxRTF2Lkm1PUDPxE1?M1fMR3NCVkeHUh?=
MKN7MkT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmrRTWM2OD1zNT6wNFk{KM7:TR?=Mn75V2FPT0WU
U-87-MGNF\VfpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVP6U482UUN3ME2xOU4xQDl5IN88US=>M4GybnNCVkeHUh?=
OVCAR-4MkfpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoTKTWM2OD1zNT6xOFI1KM7:TR?=MWLTRW5ITVJ?
OE33MmTOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXnJR|UxRTF3LkG3NVEh|ryPMXrTRW5ITVJ?
EC-GI-10NYPRXGZqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXX5e4JQUUN3ME2xOU4zOzV5IN88US=>MUDTRW5ITVJ?
AM-38M4LGUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVLJR|UxRTF3LkK3NVch|ryPNELmXmVUSU6JRWK=
NCI-H1563NV\vZnoxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWTVUHBFUUN3ME2xOU4{PDlizszNM{nOUnNCVkeHUh?=
SCC-4NXXBWVc{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYHI[W1SUUN3ME2xOU41OTB|IN88US=>M1jnNHNCVkeHUh?=
Detroit562NVnk[3l{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXXJR|UxRTF3LkS1OFch|ryPMYPTRW5ITVJ?
PC-14Mn7NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3zWSWlEPTB;MUWuOFg3PiEQvF2=M2H1cXNCVkeHUh?=
ES3NEXxNG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWrJR|UxRTF3LkWzOkDPxE1?MVrTRW5ITVJ?
OCI-AML2MlvkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFHDb2FKSzVyPUG1Mlc3OTRizszNMnn6V2FPT0WU
LU-134-AM{S3Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmC1TWM2OD1zNT65NFE5KM7:TR?=M13F[3NCVkeHUh?=
SASNYTFNG1jT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2jNfGlEPTB;MUWuPVM4OyEQvF2=MnflV2FPT0WU
TGBC11TKBNGXlWFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFnHV3RKSzVyPUG1Mlk1OTRizszNMkfIV2FPT0WU
HOP-62MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFHiT4VKSzVyPUG1Mlk2QTdizszNNG[zeFVUSU6JRWK=
G-401MkjFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4TR[mlEPTB;MUWuPVY1QSEQvF2=MnHFV2FPT0WU
NCI-H28M4G1PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEDrXWdKSzVyPUG2MlA5PTZizszNNEnOfJpUSU6JRWK=
A204MnrWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3\BdmlEPTB;MU[uNlAxPiEQvF2=NIfqe5BUSU6JRWK=
NCI-H1299NUjvN21wT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXLud4V4UUN3ME2xOk4zOjlzIN88US=>MlPDV2FPT0WU
VMRC-RCZNVXycZF6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX\JR|UxRTF4LkK1PVIh|ryPMmLKV2FPT0WU
BxPC-3M123bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWjJR|UxRTF4LkK4OVYh|ryPMmm2V2FPT0WU
NCI-H2228M3;z[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV;JR|UxRTF4LkWxOVgh|ryPM4XJTXNCVkeHUh?=
NCI-H23MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYf2S|B7UUN3ME2xOk43ODd6IN88US=>MkSyV2FPT0WU
NKM-1MnrOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmraTWM2OD1zNz6wNVg6KM7:TR?=NFGwPI9USU6JRWK=
KYSE-70NU[y[WRsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4nnSWlEPTB;MUeuNlg6KM7:TR?=MWTTRW5ITVJ?
BB49-HNCNV;EVZQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVfuV3RVUUN3ME2xO{42Pjh4IN88US=>MVPTRW5ITVJ?
SCC-15NGmzXmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVrJR|UxRTF5Lki0O|Mh|ryPNF;HOYhUSU6JRWK=
D-247MGNXrTbI9TT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3nzdmlEPTB;MUeuPVI1PyEQvF2=MlPtV2FPT0WU
BB30-HNCMU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYX5S4lDUUN3ME2xPE4xOzF6IN88US=>NGjLbJRUSU6JRWK=
CAL-85-1M3P0N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NInvcGJKSzVyPUG4MlE5ODlizszNNUTMe3U6W0GQR1XS
HT-3MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlzLTWM2OD1zOD6zPVc4KM7:TR?=MoXIV2FPT0WU
KYSE-410M4W0[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIX5cpRKSzVyPUG4MlQ2PzdizszNM3nmZnNCVkeHUh?=
SW982NWi3dohST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NULWXVB2UUN3ME2xPE42PjR7IN88US=>NVTtWG9[W0GQR1XS
SW962NUHyPJZUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MojlTWM2OD1zOD61O|AzKM7:TR?=NEjSWmdUSU6JRWK=
Ramos-2G6-4C10MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXjpVIxQUUN3ME2xPE42QTJ5IN88US=>MYDTRW5ITVJ?
OC-314M2fvOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnzXTWM2OD1zOD63N|g1KM7:TR?=MYTTRW5ITVJ?
LS-123MkT3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NES4[5VKSzVyPUG4Mlc6ODFizszNNHuwZXdUSU6JRWK=
D-502MGMmPyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHnOcmhKSzVyPUG4MlgyOzlizszNMX3TRW5ITVJ?
RO82-W-1M3TtcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH3HS|JKSzVyPUG4MlgzQDhizszNMXrTRW5ITVJ?
HuO9M4nnVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmPzTWM2OD1zOT6xN|c6KM7:TR?=M3G2ZnNCVkeHUh?=
ETK-1NVfjVlYyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2\nPGlEPTB;MUmuNVgzPyEQvF2=NEm4fmhUSU6JRWK=
SNU-387NWrG[I1OT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWjJR|UxRTF7LkG4PFkh|ryPM37MfnNCVkeHUh?=
SW1573NEfNcVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1zme2lEPTB;MUmuNVk3QSEQvF2=NXux[mlTW0GQR1XS
NTERA-S-cl-D1NX2zem5VT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGHNSVNKSzVyPUG5MlIxODdizszNMoXsV2FPT0WU
SF126M3LmR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3ThV2lEPTB;MUmuN|UxOiEQvF2=MmCyV2FPT0WU
Calu-3MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1r5eGlEPTB;MUmuOFI{PyEQvF2=MX\TRW5ITVJ?
NCI-H1048NXPKbZJsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV[1RZN1UUN3ME2yNE4{OjZ4IN88US=>MoPtV2FPT0WU
NCI-H226NV7xSZFmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4f2bGlEPTB;MkCuOFM6QSEQvF2=MlmxV2FPT0WU
FTC-133M3S3Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWTaT29iUUN3ME2yNE41PzB|IN88US=>Mnv4V2FPT0WU
SF539MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYnGXlZWUUN3ME2yNE42OTd{IN88US=>MUDTRW5ITVJ?
TE-6NWPofJRXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M174SGlEPTB;MkCuPFA3PyEQvF2=NH;LTI5USU6JRWK=
UMC-11NVjMTZJkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXTJR|UxRTJyLkmxOlQh|ryPNHnKb5hUSU6JRWK=
BeckerM2jXTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYrJR|UxRTJzLkGxNVgh|ryPMljpV2FPT0WU
KP-4NW\ySHdqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1\GRWlEPTB;MkGuNVE6PiEQvF2=NYnleFh4W0GQR1XS
ChaGo-K-1MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUnZRnE{UUN3ME2yNU4{PjJ5IN88US=>NXHFPFhbW0GQR1XS
CFPAC-1MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWflUmdiUUN3ME2yNU4{QDV6IN88US=>MlPiV2FPT0WU
A498MonmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVvJR|UxRTJzLkWzNVIh|ryPMnn2V2FPT0WU
NCI-H1755M{[4TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2q4TmlEPTB;MkGuOlc1OSEQvF2=NXTmXWJrW0GQR1XS
TI-73M4O0d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXSxb4RCUUN3ME2yNk4{OjhizszNMnLLV2FPT0WU
NCI-H441MoW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3O3RmlEPTB;MkKuOVY5QSEQvF2=M3j3Z3NCVkeHUh?=
CaR-1MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3[4VWlEPTB;MkOuNFIyOyEQvF2=NX2wTmhVW0GQR1XS
HCC1806NEDhenpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXzJR|UxRTJ|LkC1PFMh|ryPMnzJV2FPT0WU
SNU-449MkHZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWPJR|UxRTJ|LkOyPUDPxE1?MV\TRW5ITVJ?
EKVXNFTacoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NI\rdHRKSzVyPUKzMlM6ODlizszNMYXTRW5ITVJ?
DMS-114NVLYU2hoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlXXTWM2OD1{Mz61O|Y2KM7:TR?=NEnmXZNUSU6JRWK=
A704M{WyZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3TkeWlEPTB;MkOuOlExOyEQvF2=MlPLV2FPT0WU
LC-2-adM2fnWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M33D[2lEPTB;MkOuOlE1PyEQvF2=NWC4Wo1YW0GQR1XS
VM-CUB-1NIfwbotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3jFSGlEPTB;MkOuO|M1OSEQvF2=MWLTRW5ITVJ?
PC-3MlvyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXPJR|UxRTJ2LkC1NlYh|ryPNXfKbXB[W0GQR1XS
HELNYXPO2tsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWTJR|UxRTJ2LkC4OlUh|ryPM161WHNCVkeHUh?=
ABC-1NFrDVYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlvtTWM2OD1{ND6yO|I6KM7:TR?=MkLQV2FPT0WU
COLO-680NNIDle4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4nDbWlEPTB;MkSuOFc3PCEQvF2=MkHWV2FPT0WU
MZ1-PCNXG5PW1yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnXlTWM2OD1{ND62PFch|ryPNX3lUI9YW0GQR1XS
NCI-H69MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2i0Z2lEPTB;MkSuO|M2PCEQvF2=M4CzTHNCVkeHUh?=
TE-1M3fjeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mnz5TWM2OD1{NT6wOFk6KM7:TR?=M4C0NXNCVkeHUh?=
EW-3Mk\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2\4WmlEPTB;MkWuNVE{KM7:TR?=NVzxSlBDW0GQR1XS
PANC-08-13MmmwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX:0VZVlUUN3ME2yOU45OTB|IN88US=>NUXr[3FDW0GQR1XS
NMC-G1MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnXwTWM2OD1{Nj6wNFg5KM7:TR?=NUTCXnVLW0GQR1XS
BT-20MlXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoTQTWM2OD1{Nj60OVQ{KM7:TR?=Mn[yV2FPT0WU
TGBC24TKBNF;keHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnX2TWM2OD1{Nj63N|MyKM7:TR?=Mof4V2FPT0WU
TE-11M4XacWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3nHNWlEPTB;Mk[uPVg6PSEQvF2=MVzTRW5ITVJ?
ESS-1M4TvcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFPkdHpKSzVyPUK3MlMzOTZizszNMYLTRW5ITVJ?
JVM-3MlzDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHzibnhKSzVyPUK3MlY1PzVizszNMnH6V2FPT0WU
C3AMUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3\ndGlEPTB;MkeuPFQ6PiEQvF2=Mk[xV2FPT0WU
MDA-MB-157NYPWbJRjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2DQRmlEPTB;MkeuPFc2OyEQvF2=NV\WT5FbW0GQR1XS
KLENEfFb5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX7vbJdTUUN3ME2yPE4yODV6IN88US=>M3nOWHNCVkeHUh?=
ES1MluzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3jqbGlEPTB;MkiuNVg{QCEQvF2=M{fwWnNCVkeHUh?=
CAL-120M{HFUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml;lTWM2OD1{OD6zPVk6KM7:TR?=NX3UPXFjW0GQR1XS
NCI-N87MkPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXjkU41ZUUN3ME2yPE42OTB3IN88US=>MlrzV2FPT0WU
RPMI-8226NILkXnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnjHTWM2OD1{OT6xPFQ{KM7:TR?=MWXTRW5ITVJ?
COR-L88M4nKfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX7Q[lZWUUN3ME2yPU4zPDF7IN88US=>NEf3O3pUSU6JRWK=
UACC-893NGqycZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYTEelI1UUN3ME2yPU4{OTN5IN88US=>NUXzSoNDW0GQR1XS
C8166NX2wOZRpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkPYTWM2OD1{OT65PVk3KM7:TR?=NUXrR4x3W0GQR1XS
J82MmfpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXfJR|UxRTNyLkixOFch|ryPMYLTRW5ITVJ?
PFSK-1MoLvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkLpTWM2OD1|MT6wOlU6KM7:TR?=MX\TRW5ITVJ?
COLO-684M{TRVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEGzOWJKSzVyPUOxMlQ{PzRizszNNITSS5RUSU6JRWK=
CAL-72M{LRPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX3JR|UxRTNzLkW3Nlkh|ryPMmjrV2FPT0WU
SNB75MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXXJR|UxRTNzLki5O{DPxE1?M2fwR3NCVkeHUh?=
MDA-MB-415MkOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXWzVWtRUUN3ME2zNU46PzZ{IN88US=>MmHvV2FPT0WU
SiHaM{DrOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXG4[5ByUUN3ME2zNk41PzFzIN88US=>MXfTRW5ITVJ?
NCI-H1648MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVjJR|UxRTN{LkmzOFUh|ryPNF\oXplUSU6JRWK=
EFO-21MmrES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1rtNWlEPTB;M{OuNFA2KM7:TR?=MXnTRW5ITVJ?
HCC38NIrBdpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVzzU3JlUUN3ME2zN{4{QDRzIN88US=>M{PYPXNCVkeHUh?=
IA-LMMV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXHIRlNjUUN3ME2zN{44QDh7IN88US=>MVfTRW5ITVJ?
CTV-1MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NETFW25KSzVyPUOzMlk4QDZizszNNYexfGR4W0GQR1XS
NCI-H446MlzrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHj1SVhKSzVyPUO0MlI3QDlizszNNFTBOmNUSU6JRWK=
IST-SL1MofGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4q4V2lEPTB;M{SuO|QxQCEQvF2=NXzGPFJwW0GQR1XS
EW-22MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIXad|FKSzVyPUO0Mlc4PTlizszNNFXBS4VUSU6JRWK=
JEG-3MkSxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mnj3TWM2OD1|Nj6xO|Y3KM7:TR?=M2nqZXNCVkeHUh?=
LU-65MnG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmK2TWM2OD1|Nj6yPVg2KM7:TR?=NEH4OoRUSU6JRWK=
NCI-H596M4PicWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkTrTWM2OD1|Nj65OVkyKM7:TR?=MYDTRW5ITVJ?
KNS-81-FDMXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1LOdmlEPTB;M{euNVQ2KM7:TR?=M{Wx[XNCVkeHUh?=
NCI-H1793MorHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4DX[2lEPTB;M{euO|A5PiEQvF2=M4[3N3NCVkeHUh?=
NCI-H460MnTMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXfUNph6UUN3ME2zPE4xQDd|IN88US=>Mli3V2FPT0WU
MPP-89M3jUZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mlr3TWM2OD1|OT61PFg3KM7:TR?=NGP2eZBUSU6JRWK=
D-542MGMni1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4\6TGlEPTB;M{muPFQ{PiEQvF2=MV7TRW5ITVJ?
JARM4H6bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUHZW|dZUUN3ME20NE41PzB3IN88US=>M33nfnNCVkeHUh?=
NCI-H209M1ziPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHTIOo1KSzVyPUSwMlY4PyEQvF2=NYCwboo6W0GQR1XS
G-402MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVXJR|UxRTRzLkO5PVMh|ryPMlvvV2FPT0WU
IST-MES1NFWxW5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4DIUmlEPTB;NEKuNVk{PSEQvF2=NGT0PVZUSU6JRWK=
DaoyMVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUjJR|UxRTR{LkW0O|Eh|ryPMkPSV2FPT0WU
EW-11NUj3cZc2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXzGcZZuUUN3ME20N{4yOjFzIN88US=>MkL2V2FPT0WU
Saos-2NICzSXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWLWUWdzUUN3ME20N{4yPTN5IN88US=>MWDTRW5ITVJ?
no-10MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoLvTWM2OD12Mz6xO|AzKM7:TR?=Mn3yV2FPT0WU
HCC1395MkLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWTEN5BzUUN3ME20N{41PjR2IN88US=>NH\ndHBUSU6JRWK=
HCE-4NVf5TG43T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mlv6TWM2OD12Mz63OlY1KM7:TR?=M3;2cnNCVkeHUh?=
EW-1MmHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV3hR|BbUUN3ME20N{45ODR7IN88US=>M2\hZnNCVkeHUh?=
OCUB-MNG\CeVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MU\JR|UxRTR2LkO2N|gh|ryPMXvTRW5ITVJ?
IGR-1Mn2wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX3ldmRTUUN3ME20OE41OTF3IN88US=>NE\EbFZUSU6JRWK=
NCI-H1838M1;Lb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGL3TpNKSzVyPUS0MlQ{PDlizszNMkL1V2FPT0WU
NCI-H2405M3TXcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVnSNJFGUUN3ME20OE42OzRizszNNF;WRlBUSU6JRWK=
GB-1MkLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWHKZWhZUUN3ME20OE44PDZ|IN88US=>NUPa[oRkW0GQR1XS
MG-63NGfPR|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVzJR|UxRTR4LkC2PVYh|ryPM1jOUHNCVkeHUh?=
KP-N-YNNHLD[3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{HEV2lEPTB;NE[uOFY4QSEQvF2=MmrJV2FPT0WU
no-11NVroSIxtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV;nUYZxUUN3ME20O{4xOjR2IN88US=>MYLTRW5ITVJ?
SW948MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnX0TWM2OD12Nz6zN|c4KM7:TR?=MUjTRW5ITVJ?
CAMA-1Mk\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXnBU|ltUUN3ME20O{4{PDN6IN88US=>MoPTV2FPT0WU
HCC1187MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYXIWZhTUUN3ME20O{42OSEQvF2=MlS3V2FPT0WU
D-392MGMl[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIfTUIlKSzVyPUS3MlY2OTZizszNNF3nRWZUSU6JRWK=
647-VMV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NX20WGRUUUN3ME20PU4{PDF2IN88US=>MUnTRW5ITVJ?

... Click to View More Cell Line Experimental Data

In vivo Oral dosing of CI-1040 impairs the growth of colon tumor xenografts of mouse and human with a wide dose range of 48-200 mg/kg per dose, but not of P388 leukemia. [1] CI-1040 inhibits the tumor xenografts from PTC cells carrying a BRAF mutation with 31.3% reduction, carrying the RET/PTC1 rearrangement with 47.5% reduction than in untreated (vehicle) mice after 3 weeks of oral administration (300 mg/kg/d). No toxic effects are observed in any mice when they are treated with CI-1040. [2] Transient exposure of mammary tumors to CI-1040 and UCN-01 causes tumor cell death in vivo and prolonged suppression of tumor regrowth. Combined treatment with CI-1040 (25 mg/kg) and UCN-01 (0.1-0.2 mg/kg) significantly reduces MDA-MB-231, and largely abolishs MCF7 tumor growth in implanted athymic mice, while either single treatment has no significant activity. The drug combination leads to profound tumor cell death which correlates with a reduction in the phosphorylation of ERK1/2 and the immuno-reactivity of Ki67 and of CD31. [5]
Features First MEK inhibitor to begin clinical development.

Protocol(Only for Reference)

Kinase Assay:

[2]

MEK1 Assay MAP kinase is activated after phosphorylation by MEK; the activated MAP kinase subsequently phosphorylates myelin basic protein (MBP).Incorporation of 32P into myelin basic protein (MBP) is assayed in the presence of glutathione S-transferase (GST) fusion proteins containing the 44-kDa MAPK (GST-MAPK) or the 45-kDa MEK (GST-MEK1). Assays are conducted in 50μL of 50 mM Tris, pH 7.4/10 mM MgCl2 /2 mM EGTA/10 μM [γ-32P]ATP containing 10 μg of GST-MEK1, 0.5 μg of GST-MAPK, and 40 μg of MBP. After incubation at 30°C for 15 minutes, reactions are stopped by addition of Laemmli SDS sample buffer. Phosphorylated MBP is resolved by SDS/10% PAGE. This screening effort leads to the discovery of several small-molecule inhibitors of MEK, i.e. CI-1040. Experiments assessing the order of addition shows that CI-1040 directly inhibits MEK1 with a 50% inhibitory concentration (IC50) of 17 nM, without affecting the activity of MAPK.

Cell Assay:

[1]

Cell lines Colon 26 carcinoma cells
Concentrations 0.1-10 μM
Incubation Time 24 hours
Method

Cells are planted seeded in T-75 cm 2 flasks and treated the next day for 24 hous with either DMSO or CI-1040. Single-cell suspensions are collected, and pellets are fixed in ice-cold ethanol (70%) for 30 minutes. After centrifugation of the samples, propidium iodide (50 μg/mL) and RNase (30 units/mL) are added to the pellets for 20 minutes at 37 °C. After filtration, samples are analyzed by flow cytometry.

Animal Study:

[3]

Animal Models PTC cells in athymic mice
Formulation Cremophor EL–95% ethanol (50:50) and dilutes with water
Dosages 150 mg/kg
Administration Orally twice daily

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Sebolt-Leopold JS, et al. Nat Med, 1999, 5(7), 810-816.

[2] Davies SP, et al. Biochem J, 2000, 135(1), 95-105.

view more

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2016-07-30)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT00033384 Completed Breast Cancer|Colorectal Cancer|Lung Cancer|Pancreatic Cancer University of Alabama at Birmingham|National Cancer Insti  ...more University of Alabama at Birmingham|National Cancer Institute (NCI) February 2002 Phase 2
NCT00034827 Completed Colorectal Neoplasms|Breast Neoplasms|Carcinoma, Non-Small-Cell Lung|Pancreatic Neoplasms Pfizer January 2002 Phase 2

Chemical Information

Download PD184352 (CI-1040) SDF
Molecular Weight (MW) 478.67
Formula

C17H14ClF2IN2O2

CAS No. 212631-79-3
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms N/A
Solubility (25°C) * In vitro DMSO 96 mg/mL (200.55 mM)
Ethanol 14 mg/mL (29.24 mM)
Water <1 mg/mL (<1 mM)
In vivo 30% PEG400+0.5% Tween80+5% propylene glycol, pH 9 10 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name 2-(2-chloro-4-iodophenylamino)-N-(cyclopropylmethoxy)-3,4-difluorobenzamide

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related MEK Products

  • Cobimetinib (GDC-0973, RG7420)

    Cobimetinib (GDC-0973, RG7420) is a potent and highly selective MEK1 inhibitor with IC50 of 4.2 nM. Phase 3.

  • BI-847325

    BI-847325 is an orally bioavailable, and selective dual MEK/Aurora kinase inhibitor with IC50 of 3 nM, 25 nM, 15 nM, 25 nM, and 4 nM for Xenopus laevis Aurora B, human Aurora A and Aurora C, as well as human MEK1 and MEK2, respectively. Phase 1.

  • GDC-0623

    GDC-0623 is a potent and ATP-uncompetitive MEK1 inhibitor with Ki of 0.13 nM. Phase 1.

  • Trametinib (GSK1120212)

    Trametinib (GSK1120212) is a highly specific and potent MEK1/2 inhibitor with IC50 of 0.92 nM/1.8 nM in cell-free assays, no inhibition of the kinase activities of c-Raf, B-Raf, ERK1/2.

    Features:More potent than PD0325901 or AZD6244.

  • PD0325901

    PD0325901 is a selective and non ATP-competitive MEK inhibitor with IC50 of 0.33 nM in cell-free assays, roughly 500-fold more potent than CI-1040 on phosphorylation of ERK1 and ERK2. Phase 2.

  • Selumetinib (AZD6244)

    Selumetinib (AZD6244) is a potent, highly selective MEK1 inhibitor with IC50 of 14 nM in cell-free assays, also inhibits ERK1/2 phosphorylation with IC50 of 10 nM, no inhibition to p38α, MKK6, EGFR, ErbB2, ERK2, B-Raf, etc. Phase 3.

    Features:First MEK inhibitor being tested in Phase II clinical trials.

  • U0126-EtOH

    U0126-EtOH is a highly selective inhibitor of MEK1/2 with IC50 of 0.07 μM/0.06 μM in cell-free assays, 100-fold higher affinity for ΔN3-S218E/S222D MEK than PD98059.

    Features:A chemically synthesized and highly selective inhibitor of both MEK1 and MEK2.

  • PD98059

    PD98059 is a non-ATP competitive MEK inhibitor with IC50 of 2 μM in a cell-free assay, specifically inhibits MEK-1-mediated activation of MAPK; does not directly inhibit ERK1 or ERK2.

    Features:Does not inhibit c-Raf phosphorylated MEK1.

  • Binimetinib (MEK162, ARRY-162, ARRY-438162)

    Binimetinib (MEK162, ARRY-162, ARRY-438162) is a potent inhibitor of MEK1/2 with IC50 of 12 nM in a cell-free assay. Phase 3.

  • Refametinib (RDEA119, Bay 86-9766)

    Refametinib (RDEA119, Bay 86-9766) is a potent, ATP non-competitive and highly selective inhibitor of MEK1 and MEK2 with IC50 of 19 nM and 47 nM, respectively.

Recently Viewed Items

Tags: buy PD184352 (CI-1040) | PD184352 (CI-1040) supplier | purchase PD184352 (CI-1040) | PD184352 (CI-1040) cost | PD184352 (CI-1040) manufacturer | order PD184352 (CI-1040) | PD184352 (CI-1040) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us